Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease.

Lenders, Malte; Boutin, Michel; Auray-Blais, Christiane; Brand, Eva

Lenders, Malte; Boutin, Michel; Auray-Blais, Christiane; Brand, Eva.

Afiliación

Lenders M; Department of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Muenster, Germany.
Boutin M; Department of Pediatrics, Division of Medical Genetics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Auray-Blais C; Department of Pediatrics, Division of Medical Genetics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Brand E; Department of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Muenster, Germany. Electronic address: Eva.Brand@ukmuenster.de.

Gastroenterology ; 159(4): 1602-1604, 2020 10.

Article en En | MEDLINE | ID: mdl-32534932

Asunto(s)

Enfermedad de Fabry/complicaciones; Enfermedades Gastrointestinales/tratamiento farmacológico; alfa-Galactosidasa/administración & dosificación; Administración Oral; Adulto; Estudios de Cohortes; Suplementos Dietéticos; Enfermedad de Fabry/tratamiento farmacológico; Femenino; Enfermedades Gastrointestinales/etiología; Humanos; Masculino; Persona de Mediana Edad

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Fabry / Alfa-Galactosidasa / Enfermedades Gastrointestinales Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google